CKCaroline B. Kurtz

Caroline B. Kurtz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Caroline B. Kurtz has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Proposed New Path for Management of Health in Inherited Metabolic Disorders Using Engineered Probiotic Bacteria

    by Caroline B Kurtz, Mona S Calvo

    Dietary supplements represent a growing segment of the healthcare industry as consumers seek alternative methods to manage health concerns. Probiotics are dietary supplements that are broadly used to aid digestion and immune and metabolic health. Patients with disorders restricting the intake of particular nutrients must balance adequate nutrition with limitations in the intake of natural food ingredients. Synthetic biology has emerged in the last decade, allowing scientists to specifically engineer probiotic bacteria to perform functions in the GI tract, such as the elimination or reduction of specific nutrients from ingested food sources. Engineered probiotic bacteria have the potential to provide health benefits and improve the quality of life of patients with genetic or acquired metabolic disorders. One way to make them available to consumers is to develop specialized products as dietary supplements. Developers of such innovative products must follow new FDA guidance and work closely with FDA in consideration of the design, development, manufacturing, and labeling of engineered probiotics as dietary supplements.


  • Top Cited Papers

    Efficacy and safety of a synthetic biotic for treatment of phenylketonuria: a phase 2 clinical trial

    by Jerry Vockley, Neal Sondheimer, Marja Puurunen, George A. Diaz, Ilona Ginevic, Dorothy K. Grange, Cary Harding, Hope Northrup, John A. Phillips, Shawn Searle, et al.

    Despite available treatment options, many patients with phenylketonuria (PKU) cannot achieve target plasma phenylalanine (Phe) levels1. We previously modified Escherichia coli Nissle 1917 to metabolize Phe in the gut after oral administration (SYNB1618) and designed a second strain (SYNB1934) with enhanced activity of phenylalanine ammonia lyase2,3. In a 14-day open-label dose-escalation study (Synpheny-1, NCT04534842), we test a primary endpoint of change from baseline in labeled Phe (D5-Phe AUC0−24; D5-Phe area under the curve (AUC) over 24 hours after D5-Phe administration) in plasma after D5-Phe challenge in adult participants with screening Phe of greater than 600 µM. Secondary endpoints were the change from baseline in fasting plasma Phe and the incidence of treatment-emergent adverse events. A total of 20 participants (ten male and ten female) were enrolled and 15 completed the study treatment. Here, we show that both strains lower Phe levels in participants with PKU: D5-Phe AUC0−24 was reduced by 43% from baseline with SYNB1934 and by 34% from baseline with SYNB1618. SYNB1934 led to a decrease in fasting plasma Phe of 40% (95% CI, −52, −24). There were no serious adverse events or infections. Four participants discontinued because of adverse events, and one withdrew during the baseline period. We show that synthetic biotics can metabolize Phe in the gut, lower post-prandial plasma Phe levels and lower fasting plasma Phe in patients with PKU.


  • Publisher Correction: Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study

    by Marja K. Puurunen, Jerry Vockley, Shawn L. Searle, Stephanie J. Sacharow, John A. Phillips, William S. Denney, Benjamin D. Goodlett, David A. Wagner, Larry Blankstein, Mary J. Castillo, et al.


  • Top Cited Papers

    Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study

    by Marja K. Puurunen, Jerry Vockley, Shawn L. Searle, Stephanie J. Sacharow, John A. Phillips, William S. Denney, Benjamin D. Goodlett, David A. Wagner, Larry Blankstein, Mary J. Castillo, et al.

    Phenylketonuria (PKU) is a rare disease caused by biallelic mutations in the PAH gene that result in an inability to convert phenylalanine (Phe) to tyrosine, elevated blood Phe levels and severe neurological complications if untreated. Most patients are unable to adhere to the protein-restricted diet, and thus do not achieve target blood Phe levels. We engineered a strain of E. coli Nissle 1917, designated SYNB1618, through insertion of the genes encoding phenylalanine ammonia lyase and l-amino acid deaminase into the genome, which allow for bacterial consumption of Phe within the gastrointestinal tract. SYNB1618 was studied in a phase 1/2a randomized, placebo-controlled, double-blind, multi-centre, in-patient study (NCT03516487) in adult healthy volunteers (n = 56) and patients with PKU and blood Phe level ≥600 mmol l−1 (n = 14). Participants were randomized to receive a single dose of SYNB1618 or placebo (part 1) or up to three times per day for up to 7 days (part 2). The primary outcome of this study was safety and tolerability, and the secondary outcome was microbial kinetics. A D5-Phe tracer (15 mg kg−1) was used to study exploratory pharmacodynamic effects. SYNB1618 was safe and well tolerated with a maximum tolerated dose of 2 × 1011 colony-forming units. Adverse events were mostly gastrointestinal and of mild to moderate severity. All participants cleared the bacteria within 4 days of the last dose. Dose-responsive increases in strain-specific Phe metabolites in plasma (trans-cinnamic acid) and urine (hippuric acid) were observed, providing a proof of mechanism for the potential to use engineered bacteria in the treatment of rare metabolic disorders.


  • Randomized, placebo-controlled study of lyophilized formulation of SYNB1618 in healthy adult volunteers

    by Marja Puurunen, William Denney, Shawn Searle, Larry Blankstein, Caroline Kurtz, Aoife Brennan, Richard Riese

  • Open Access

    Development of an engineered probiotic for the treatment of branched chain amino acid related metabolic diseases

    by Ning Li, Alex Tucker, Jian-Rong Gao, Lauren Renaud, Michael James, Mary Castillo, Silvia Galvan, Rishi Jain, Ryan Putman, Scott Marr, et al.

    Metabolic dysfunction arising from missing or impaired enzymes comprising the branched chain amino acid (BCAA) degradation pathway, especially those involving leucine, can result in the accumulation of toxic metabolic intermediates and cause severe metabolic disease. Removal of dietary BCAAs via their degradation by engineered microbes could be a viable approach to prevent BCAA-mediated disease sequelae. In this article, we describe the design and construction of an engineered leucine degrading strain of E. coli Nissle, the improvement of the degradation pathway through high throughput screening, and the demonstration of strain activity in animal models monitored by disease and strain-specific biomarkers. This work provides a path for the development of engineered probiotic bacterial strains as a treatment for BCAA-related metabolic disorders in humans.

  • Top Cited Papers
    Open Access

    Developing a new class of engineered live bacterial therapeutics to treat human diseases

    by Mark R. Charbonneau, Vincent M. Isabella, Ning Li, Caroline B. Kurtz

    A complex interplay of metabolic and immunological mechanisms underlies many diseases that represent a substantial unmet medical need. There is an increasing appreciation of the role microbes play in human health and disease, and evidence is accumulating that a new class of live biotherapeutics comprised of engineered microbes could address specific mechanisms of disease. Using the tools of synthetic biology, nonpathogenic bacteria can be designed to sense and respond to environmental signals in order to consume harmful compounds and deliver therapeutic effectors. In this perspective, we describe considerations for the design and development of engineered live biotherapeutics to achieve regulatory and patient acceptance.


  • Top Cited Papers
    Open Access

    The Effect of Psyllium Husk on Intestinal Microbiota in Constipated Patients and Healthy Controls

    by Jonna Jalanka, Giles Major, Kathryn Murray, Gulzar Singh, Adam Nowak, Caroline Kurtz, Inmaculada Silos-Santiago, Jeffrey M. Johnston, Willem M. de Vos, Robin Spiller

    Psyllium is a widely used treatment for constipation. It traps water in the intestine increasing stool water, easing defaecation and altering the colonic environment. We aimed to assess the impact of psyllium on faecal microbiota, whose key role in gut physiology is being increasingly recognised. We performed two randomised, placebo-controlled, double-blinded trials comparing 7 days of psyllium with a placebo (maltodextrin) in 8 healthy volunteers and 16 constipated patients respectively. We measured the patients’ gastrointestnal (GI) transit, faecal water content, short-chain fatty acid (SCFA) and the stool microbiota composition. While psyllium supplement had a small but significant effect on the microbial composition of healthy adults (increasing Veillonella and decreasing Subdoligranulum), in constipated subjects there were greater effects on the microbial composition (increased Lachnospira, Faecalibacterium, Phascolarctobacterium, Veillonella and Sutterella and decreased uncultured Coriobacteria and Christensenella) and alterations in the levels of acetate and propionate. We found several taxa to be associated with altered GI transit, SCFAs and faecal water content in these patients. Significant increases in three genera known to produce butyrate, Lachnospira, Roseburia and Faecalibacterium, correlated with increased faecal water. In summary, psyllium supplementation increased stool water and this was associated with significant changes in microbiota, most marked in constipated patients.


  • Top Cited Papers

    An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans

    by Caroline B. Kurtz, Yves A. Millet, Marja K. Puurunen, Mylène Perreault, Mark R. Charbonneau, Vincent M. Isabella, Jonathan W. Kotula, Eugene Antipov, Yossi Dagon, William S. Denney, et al.

    An engineered E. coli strain lowers blood ammonia, improves survival in models of hyperammonemia, and demonstrates safety in healthy volunteers.


  • Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction

    by Luke Grundy, Andrea M. Harrington, Joel Castro, Sonia Garcia-Caraballo, Annemie Deiteren, Jessica Maddern, Grigori Y. Rychkov, Pei Ge, Stefanie Peters, Robert Feil, et al.

    Irritable bowel syndrome (IBS) patients suffer from chronic abdominal pain and extraintestinal comorbidities, including overactive bladder (OAB) and interstitial cystitis/painful bladder syndrome (IC-PBS). Mechanistic understanding of the cause and time course of these comorbid symptoms is lacking, as are clinical treatments. Here, we report that colitis triggers hypersensitivity of colonic afferents, neuroplasticity of spinal cord circuits, and chronic abdominal pain, which persists after inflammation. Subsequently, and in the absence of bladder pathology, colonic hypersensitivity induces persistent hypersensitivity of bladder afferent pathways, resulting in bladder-voiding dysfunction, indicative of OAB/IC-PBS. Daily administration of linaclotide, a guanylate cyclase-C (GC-C) agonist that is restricted to and acts within the gastrointestinal tract, reverses colonic afferent hypersensitivity, reverses neuroplasticity-induced alterations in spinal circuitry, and alleviates chronic abdominal pain in mice. Intriguingly, daily linaclotide administration also reverses persistent bladder afferent hypersensitivity to mechanical and chemical stimuli and restores normal bladder voiding. Linaclotide itself does not inhibit bladder afferents, rather normalization of bladder function by daily linaclotide treatment occurs via indirect inhibition of bladder afferents via reduced nociceptive signaling from the colon. These data support the concepts that cross-organ sensitization underlies the development and maintenance of visceral comorbidities, while pharmaceutical treatments that inhibit colonic afferents may also improve urological symptoms through common sensory pathways.